Reviews
28 August 2025
Early Access
The impact of tocilizumab on hepatic enzyme levels in rheumatoid arthritis patients: a narrative review
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
23
Views
13
Downloads
Authors
Rheumatoid arthritis (RA) is an autoimmune disease affecting 0.5-1% of the global population. Tocilizumab (TCZ), a monoclonal antibody, offers a promising treatment option for RA patients unresponsive to disease-modifying antirheumatic drugs (DMARDs). While multiple studies have demonstrated the efficacy and safety of TCZ, some have reported associations between TCZ treatment and elevations in hepatic transaminase levels. This review explores the relationship between TCZ therapy and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in RA patients previously treated with DMARDs. For this narrative review, a comprehensive search was conducted in two major databases, PubMed and Google Scholar, for articles published in English between 2013 and 2023. The search utilized key terms such as "tocilizumab", "hepatic transaminases", "ALT", "AST", "rheumatoid arthritis patients", and "DMARDs". From 402 initially identified articles, 10 studies published between 2013 and 2023 were selected for review, including observational studies, narrative reviews, and systematic reviews. These studies examined the impact of TCZ on liver enzyme levels in RA patients receiving DMARDs, with varying sample sizes. TCZ demonstrates clinical efficacy in patients with RA unresponsive to previous treatments. Although mild and transient elevations in liver enzymes, particularly ALT, have been observed, serious hepatic adverse events remain uncommon. Although current evidence indicates that TCZ shows promise as a treatment for RA, the variability among studies and the quality of the included evidence call for a careful interpretation of the findings. Continued liver function monitoring and individualized dosing are recommended to support its safe use.
Altmetrics
Downloads
Download data is not yet available.
Citations
Navarro-Millán I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 2012;34:788-802.e3. DOI: https://doi.org/10.1016/j.clinthera.2012.02.014
Jahid M, Ullah K, Karim U, et al. Overview of rheumatoid arthritis and scientific understanding of the disease. Mediterr J Rheumatol 2017;28:223-6.
Genovese MC, Kremer JM, van Vollenhoven RF, et al. Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis. Arthritis Rheumatol 2017;69:1751-61. DOI: https://doi.org/10.1002/art.40176
Saki A, Rajaei E, Rahim F. Safety and efficacy of tocilizumab for rheumatoid arthritis: a systematic review and meta-analysis of clinical trial studies. Reumatologia 2021;59:169-79. DOI: https://doi.org/10.5114/reum.2021.107026
Rigby WFC, Lampl K, Low JM, Furst DE. Review of routine laboratory monitoring for patients with rheumatoid arthritis receiving biologic or nonbiologic DMARDs. Int J Rheumatol 2017;2017:9614241. DOI: https://doi.org/10.1155/2017/9614241
Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2010;3:81-9. DOI: https://doi.org/10.4137/CMAMD.S4864
Van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YPM, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent-onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 2007;66:1356-62. DOI: https://doi.org/10.1136/ard.2006.066662
Singh JA, Saba B, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2011;38:10-20. DOI: https://doi.org/10.3899/jrheum.100717
Specker C, Alberding A, Aringer M, et al. ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. Clin Exp Rheumatol 2021;39:319-28. DOI: https://doi.org/10.55563/clinexprheumatol/3qdgi1
Behrens F, Burmester GR, Hofmann MW, et al. Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational study. Clin Exp Rheumatol 2023;41:1463-72. DOI: https://doi.org/10.55563/clinexprheumatol/hlmsao
Parisi S, Becciolini A, Ditto MC, et al. Ab0341 efficacy and drug survival after multiple-switching from adalimumab originator to the biosimilars ABP501 and SB5: a real-life study. Ann Rheum Dis 2022;81:1295-6. DOI: https://doi.org/10.1136/annrheumdis-2022-eular.1828
Bannwarth B, Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 2011;10:123-31. DOI: https://doi.org/10.1517/14740338.2011.537256
Sanmartí R, Ruiz-Esquide V, Bastida C, et al. Tocilizumab in the treatment of adult rheumatoid arthritis. Immunotherapy 2018;10:447-64. DOI: https://doi.org/10.2217/imt-2017-0173
Baganz L, Richter A, Kekow J, et al. Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort. Rheumatol Int 2018;38:579-87. DOI: https://doi.org/10.1007/s00296-017-3870-7
LiverTox. Severity grading in drug-induced liver injury. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD, USA: National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
Wells GA, O’Connell D, Peterson J, et al. Newcastle-Ottawa quality assessment scale. Ottawa Hospital Research Institute 2014;3:2-4.
Li L, Asemota I, Liu B, et al. AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals. Syst Rev 2022;11:147. DOI: https://doi.org/10.1186/s13643-022-02029-9
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:I4898. DOI: https://doi.org/10.1136/bmj.l4898
Baethge C, Goldbeck-Wood S, Mertens S. SANRA - a scale for the quality assessment of narrative review articles. Res Integr Peer Rev 2019;4:5. DOI: https://doi.org/10.1186/s41073-019-0064-8
Brazdilova K, Koller T, Killinger Z, Payer J. Prevalence and risk factors for drug-induced liver injury among patients with rheumatic diseases treated with biological therapy: a single-center experience. Physiol Res 2019;68:S157-63. DOI: https://doi.org/10.33549/physiolres.934299
Kaneko A. Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy. Ther Adv Chronic Dis 2013;4:15-21. DOI: https://doi.org/10.1177/2040622312466908
İnanç GN, Terzioğlu ME, Karabulut Y, et al. A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors. Turk J Med Sci 2023;53:731-43. DOI: https://doi.org/10.55730/1300-0144.5636
Curtis JR, Perez-Gutthann S, Suissa S, et al. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. Semin Arthritis Rheum 2015;44:381-8. DOI: https://doi.org/10.1016/j.semarthrit.2014.07.006
Zhao X, Zhang C, An Y, et al. Research on liver damage caused by the treatment of rheumatoid arthritis with novel biological agents or targeted agents. J Inflamm Res 2023;16:443-52. DOI: https://doi.org/10.2147/JIR.S395137
Bykerk VP, Östör AJK, Alvaro-Gracia J, et al. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clin Rheumatol 2015;34:563-71. DOI: https://doi.org/10.1007/s10067-014-2857-y
Álvaro-Gracia JM, Fernández-Nebro A, García-López A, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice. Reumatol Clin 2014;10:94-100. DOI: https://doi.org/10.1016/j.reumae.2013.12.018
Backhaus M, Kaufmann J, Richter C, et al. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. Clin Rheumatol 2015;34:673-81. DOI: https://doi.org/10.1007/s10067-015-2879-0
Best JH, Kuang Y, Jiang Y, et al. Comparative efficacy (DAS28 remission) of targeted immune modulators for rheumatoid arthritis: a network meta-analysis. Rheumatol Ther 2021;8:693-710. DOI: https://doi.org/10.1007/s40744-021-00322-y
How to Cite
The impact of tocilizumab on hepatic enzyme levels in rheumatoid arthritis patients: a narrative review. (2025). Italian Journal of Medicine. https://doi.org/10.4081/itjm.2025.2000
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Ombretta Para, Pietro Crispino, Nunzia Barone, Sara Macis, Laura Airasca, Paola Gnerre, Cecilia Politi, Sex differences in adverse drug reaction and liver disease , Italian Journal of Medicine: Vol. 12 No. 1 (2018)
- Mario Visconti, Proton pump inhibitors overuse: only inappropriate prescriptions or further iatrogenic damage? , Italian Journal of Medicine: Vol. 9 No. 3 (2015)
- Elena Garlatti Costa, Cesare Mazzaro, Alessandro Grembiale, Alessandro Berto, Rita De Rosa, Silvia Grazioli, Maurizio Tonizzo, HIV, HCV and SARS-CoV-2: friends or foes? A case report , Italian Journal of Medicine: Vol. 15 No. 3 (2021)
- Balzarini Laura, Chiara Mancini, Mario Uccelli, Enrico Betri, Maurizio Marvisi, Acute pneumonitis or vasculitis? A severe case with multiple organ involvement , Italian Journal of Medicine: Vol. 9 No. 4 (2015)
- Aurelio Seidita, Delia Sprini, Accursia Bongiovì, Tiziana Catalano, Filippo Barbiera, Maria Accardi, Pasquale Mansueto, Antonio Carroccio, Portal vein thrombosis and Budd-Chiari syndrome as onset of polycythemia vera , Italian Journal of Medicine: Vol. 7 No. 3 (2013)
- Massimo L'Andolina, Giovanni Forte, Norma M. Marigliano, Salvatore Galasso, Francesca Mazzei, Domenico Galasso, Present and future management of anti-neutrophil cytoplasmic antibody associated vasculitis: how therapy changed the prognosis , Italian Journal of Medicine: Vol. 7 No. 1 (2013)
- Yasir Mehmood, Hira Shahid, Aysha Tariq, Syeda Omama Ali, Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trial , Italian Journal of Medicine: Vol. 16 No. 1 (2022)
- P21 | A case of acute hepatitis: does therapy lead to a diagnosis? , Italian Journal of Medicine: Vol. 19 No. 1(s1) (2025): XXX FADOI Italian Congress | 10-12 May 2025
- Francesca Salvotti, Riccardo Pellegrinelli, Veronica Geroldi, Francesca Leidi, Vittorio Scipione, Gigliola Flamminio, Antonella Pastori, Claudia Agabiti-Rosei, Carolina De Ciuceis, Damiano Rizzoni, Gianluca Edoardo Mario Boari, Long-term impact of COVID-19 requiring elevated oxygen support and safety of prolonged positive pressure ventilation , Italian Journal of Medicine: Vol. 17 No. 3 (2023)
- Cristina Cenci, Tea Restuccia, Paola Gnerre, Irene Chiti, Laura Betti, Milena Micati, Claudio Tana, The management of the patient with acute pancreatitis: from evidence to clinical practice , Italian Journal of Medicine: Vol. 11 No. 3 (2017)
You may also start an advanced similarity search for this article.